TNF α mediated IL-6 secretion is regulated by JAK/STAT pathway but not by MEK phosphorylation and AKT phosphorylation in U266 multiple myeloma cells

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Lee, Chansu ^a   Oh, Jeong In ^a   Park, Juwon ^a   Choi, Jee Hye ^a   Bae, Eun Kyung ^b   Lee, Hyun Jung ^c   Jung, Woo June ^a   Lee, Dong Soon ^a,b   Ahn, Kwang Sung ^b   Yoon, Sung Soo ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Dongguk University Ilsan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GAMMA INTERFERON; I KAPPA B BETA; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; I KAPPA B KINASE; IL6 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; STAT PROTEIN;

ADULT; AGED; ARTICLE; CELL GROWTH; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA BINDING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; BIOSYNTHESIS; BONE MARROW; DRUG ANTAGONISM; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CELL LINE, TUMOR; FEMALE; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-6; JANUS KINASE 2; MALE; MAP KINASE KINASE KINASES; MIDDLE AGED; MULTIPLE MYELOMA; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885661201     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/580135     Document Type: Article

References (31)

1. Hideshima T., Anderson K. C., Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer 2002 2 12 927 937 2-s2.0-0036884062 10.1038/nrc952 (Pubitemid 37328894)
2. Singhal S., Mehta J., Novel therapies in multiple myeloma. International Journal of Hematology 2003 77 3 226 231 2-s2.0-0141569473 (Pubitemid 37121847)
3. Hideshima T., Chauhan D., Podar K., Schlossman R. L., Richardson P., Anderson K. C., Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology 2001 28 6 607 612 2-s2.0-0035211881 (Pubitemid 33134420)
4. Meads M. B., Hazlehurst L. A., Dalton W. S., The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research 2008 14 9 2519 2526 2-s2.0-52049103847 10.1158/1078-0432.CCR-07-2223
5. Nefedova Y., Landowski T. H., Dalton W. S., Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003 17 6 1175 1182 2-s2.0-0038717067 10.1038/sj.leu.2402924 (Pubitemid 36722250)
6. Podar K., Richardson P. G., Hideshima T., Chauhan D., Anderson K. C., The malignant clone and the bone-marrow environment. Best Practice and Research in Clinical Haematology 2007 20 4 597 612 2-s2.0-36749011232 10.1016/j.beha.2007. 08.002 (Pubitemid 350215375)
7. Mitsiades C. S., McMillin D. W., Klippel S., Hideshima T., Chauhan D., Richardson P. G., Munshi N. C., Anderson K. C., The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematology/Oncology Clinics of North America 2007 21 6 1007 1034 2-s2.0-35748930596 10.1016/j.hoc.2007.08.007 (Pubitemid 350051349)
8. Alexandrakis M. G., Passam F. H., Sfiridaki A., Kandidaki E., Roussou P., Kyriakou D. S., Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. The American Journal of Hematology 2003 72 4 229 233 2-s2.0-0037381271 10.1002/ajh.10304 (Pubitemid 36383972)
9. Cao Y., Luetkens T., Kobold S., Hildebrandt Y., Gordic M., Lajmi N., Meyer S., Bartels K., Zander A. R., Bokemeyer C., Kröger N., Atanackovic D., The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Experimental Hematology 2010 38 10 860 867 2-s2.0-77956581743 10.1016/j.exphem.2010.06.012
10. Aggarwal R., Ghobrial I. M., Roodman G. D., Chemokines in multiple myeloma. Experimental Hematology 2006 34 10 1289 1295 2-s2.0-33748614845 10.1016/j.exphem.2006.06.017 (Pubitemid 44376817)
11. Coe L. M., Irwin R., Lippner D., McCabe L. R., The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. Journal of Cellular Physiology 2011 226 2 477 483 2-s2.0-78649672809 10.1002/jcp.22357
12. Lu X., Beck G. R. Jr., Gilbert L. C., Camalier C. E., Bateman N. W., Hood B. L., Conrads T. P., Kern M. J., You S., Chen H., Nanes M. S., Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation. Journal of Bone and Mineral Research 2011 26 1 209 219 2-s2.0-78650950392 10.1002/jbmr.203
13. Bommert K., Bargou R. C., Stühmer T., Signalling and survival pathways in multiple myeloma. European Journal of Cancer 2006 42 11 1574 1580 2-s2.0-33746378638 10.1016/j.ejca.2005.12.026 (Pubitemid 44118772)
14. Kawano M. M., Ishikawa H., Tsuyama N., Abroun S., Liu S., Li F., Otsuyama K., Zheng X., Growth mechanism of human myeloma cells by interleukin-6. International Journal of Hematology 2002 76 supplement 1 329 333 2-s2.0-0037484922
15. Devlin R. D., Reddy S. V., Savino R., Ciliberto G., Roodman G. D., IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. Journal of Bone and Mineral Research 1998 13 3 393 399 2-s2.0-0031895576 10.1359/jbmr.1998.13.3.393 (Pubitemid 28146221)
16. Baud V., Karin M., Is NF- B a good target for cancer therapy? Hopes and pitfalls. Nature Reviews Drug Discovery 2009 8 1 33 40 2-s2.0-58149202128 10.1038/nrd2781
17. Zdzisińska B., Bojarska-Junak A., Dmoszyńska A., Kandefer-Szerszeń M., Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Archivum Immunologiae et Therapiae Experimentalis 2008 56 3 207 221 2-s2.0-45849119799 10.1007/s00005-008-0022-5
18. Prabhala R. H., Pelluru D., Fulciniti M., Prabhala H. K., Nanjappa P., Song W., Pai C., Amin S., Tai Y., Richardson P. G., Ghobrial I. M., Treon S. P., Daley J. F., Anderson K. C., Kutok J. L., Munshi N. C., Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010 115 26 5385 5392 2-s2.0-77955862810 10.1182/blood-2009-10-246660
19. Wajant H., Pfizenmaier K., Scheurich P., Tumor necrosis factor signaling. Cell Death and Differentiation 2003 10 1 45 65 2-s2.0-0037276438 10.1038/sj.cdd.4401189 (Pubitemid 36511832)
20. Chen G., Goeddel D. V., TNF-R1 signaling: a beautiful pathway. Science 2002 296 5573 1634 1635 2-s2.0-0037204948 10.1126/science.1071924 (Pubitemid 34579145)
21. Thompson M. A., Witzig T. E., Kumar S., Timm M. M., Haug J., Fonseca R., Greipp P. R., Lust J. A., Rajkumar S. V., Plasma levels of tumour necrosis factor α and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. The British Journal of Haematology 2003 123 2 305 308 2-s2.0-0142246501 10.1046/j.1365-2141.2003.04605.x (Pubitemid 37305066)
22. Sati H. I. A., Greaves M., Apperley J. F., Russell R. G. G., Croucher P. I., Expression of interleukin-1 β and tumour necrosis factor- α in plasma cells from patients with multiple myeloma. The British Journal of Haematology 1999 104 2 350 357 2-s2.0-0032589103 10.1046/j.1365-2141.1999.01193. x (Pubitemid 29083345)
23. Lichtenstein A., Berenson J., Norman D., Chang M. P., Carlile A., Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989 74 4 1266 1273 2-s2.0-0024419152 (Pubitemid 19227434)
24. Markovina S., Callander N. S., O'Connor S. L., Kim J., Werndli J. E., Raschko M., Leith C. P., Kahl B. S., Kim K., Miyamoto S., Bortezomib-resistant nuclear factor- B activity in multiple myeloma cells. Molecular Cancer Research 2008 6 8 1356 1364 2-s2.0-52449135431 10.1158/1541-7786.MCR-08-0108
25. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T. A., Anderson K. C., Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF- B. Blood 1996 87 3 1104 1112 2-s2.0-0030041147 (Pubitemid 26043538)
26. Sanda T., Iida S., Ogura H., Asamitsu K., Murata T., Bacon K. B., Ueda R., Okamoto T., Growth inhibition of multiple myeloma cells by a novel I B kinase inhibitor. Clinical Cancer Research 2005 11 5 1974 1982 2-s2.0-16344362279 10.1158/1078-0432.CCR-04-1936 (Pubitemid 40471863)
27. Dai Y., Pei X. Y., Rahmani M., Conrad D. H., Dent P., Grant S., Interruption of the NF- B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004 103 7 2761 2770 2-s2.0-1642278407 10.1182/blood-2003-09-3037 (Pubitemid 38393035)
28. Hideshima T., Neri P., Tassone P., Yasui H., Ishitsuka K., Raje N., Chauhan D., Podar K., Mitsiades C., Dang L., Munshi N., Richardson P., Schenkein D., Anderson K. C., MLN120B, a novel I B kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clinical Cancer Research 2006 12 19 5887 5894 2-s2.0-33750283069 10.1158/1078-0432.CCR-05-2501 (Pubitemid 44629622)
29. Ha K. H., Byun M. S., Choi J., Jeong J., Lee K. J., Jue D. M., N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF- B activation by blocking specific cysteine residues of I B kinase β and p65/RelA. Biochemistry 2009 48 30 7271 7278 2-s2.0-70350717978 10.1021/bi900660f
30. Wang W., Abbruzzese J. L., Evans D. B., Chiao P. J., Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999 18 32 4554 4563 2-s2.0-0033549875 10.1038/sj.onc.1202833 (Pubitemid 29405887)
31. Rokhlin O. W., Guseva N. V., Taghiyev A. F., Glover R. A., Cohen M. B., Multiple effects of N- α -tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines. Cancer Biology and Therapy 2004 3 8 761 768 2-s2.0-16644382316 (Pubitemid 41351081)